# US 9,517,287 B2 · Hemostatic sponge > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,517,287 B2 - Document ID: US9517287B2 - Status: Granted - Kind: B2 - Application number: 14/320,064 - Filed: 2014-06-30 - Published: 2014-12-25 - Granted: 2016-12-13 - Earliest claimed: 2009-12-16 - Assignees: Baxter International Inc.; Baxter Healthcare S.A. - Applicants: BAXTER International Inc.; BAXTER Healthcare S.A. - Inventors: Hans Christian Hedrich; Joris Hoefinghoff; Woonza M. Rhee; Atsushi Edward Osawa - Web page: https://patentgrep.com/patent/US9517287B2 ## CPC - A61L 15/425: {Porous materials, e.g. foams or sponges} - A61F 13/0213: {the fluid retention member being a layer of hydrocolloid, gel forming material} - A61F 13/025: {having a special distribution arrangement of the adhesive} - A61F 13/0253: {characterized by the adhesive material} - A61F 13/0289: {manufacturing of adhesive dressings} - A61F 13/15577: {Apparatus or processes for manufacturing} - A61L 15/225: {Mixtures of macromolecular compounds} - A61L 15/58: Adhesives - C08G 65/334: containing sulfur - C08L 71/02: Polyalkylene oxides - C09J 171/02: Polyalkylene oxides - A61F 13/01012: {being made of natural material, e.g. cellulose-, protein-, collagen-based} - A61F 2013/00463: {haemostatic} - A61F 2013/00468: {applying local pressure} - A61F 2013/00472: {with chemical means} - A61L 2400/04: Materials for stopping bleeding - C08L 2205/05: containing polymer components which can react with one another - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS - C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06) - C09J: ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES (preparation of glue or gelatine C09H) ## Abstract The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis. ## Claims ### Claim 1 A hemostatic composite sponge comprising a porous sponge of a matrix of a biomaterial and a material enhancing the adherence of said porous sponge to an applied tissue stably associated with at least one surface of said porous sponge, wherein said adherence-enhancing material is essentially free of a hydrogel forming component, and wherein the adherence-enhancing material is present in a grid pattern on the porous sponge. ### Claim 2 (depends on 1) The sponge according to claim 1, wherein said biomaterial is selected from the group consisting of collagen, gelatin, fibrin, a polysaccharide, and a derivative thereof. ### Claim 3 (depends on 2) The sponge according to claim 2, wherein the polysaccharide comprises chitosan. ### Claim 4 (depends on 2) The sponge according to claim 2, wherein said adherence-enhancing material is a mixture of two pre-polymers comprising a first cross-linkable component and a second cross-linkable component that cross-links with the first cross-linkable component under reaction enabling conditions. ### Claim 5 (depends on 4) The sponge according to claim 4, wherein said first and/or second cross-linkable component comprise a derivative of polyethylene glycol. ### Claim 6 (depends on 2) The sponge according to claim 2, wherein said first and/or second cross-linkable component comprise a derivative of polyethylene glycol. ### Claim 7 (depends on 1) The sponge according to claim 1, wherein said adherence-enhancing material is a mixture of two pre-polymers comprising a first cross-linkable component and a second cross-linkable component that cross-links with the first cross-linkable component under reaction enabling conditions. ### Claim 8 (depends on 7) The sponge according to claim 7, wherein said first and/or second cross-linkable component comprise a derivative of polyethylene glycol. ### Claim 9 (depends on 1) The sponge according to claim 1, wherein said first and/or second cross-linkable component comprise a derivative of polyethylene glycol. ### Claim 10 (depends on 1) The sponge according to claim 1, wherein said adherence-enhancing material forms a continuous or discontinuous layer on at least one surface of said porous sponge. ### Claim 11 (depends on 1) The sponge according to claim 1 having an overall thickness of about 1 mm to about 2.5 mm. ### Claim 12 (depends on 1) The sponge according to claim 1 for use in minimal invasive surgery. ### Claim 13 (depends on 12) The sponge according to claim 12, wherein the minimal invasive surgery comprises a laparoscopic application. ### Claim 14 (depends on 1) The sponge according to claim 1 wherein the adherence-enhancing material is present in a concentration of 5 to 500 mg per cm2 of biomaterial. ### Claim 15 (depends on 14) The sponge according to claim 14, wherein the adherence-enhancing material is present in a concentration of between 5 to 100 mg per cm2. ### Claim 16 (depends on 1) A method of treating a wound, a hemorrhage, damaged tissue and/or bleeding tissue comprising administering the hemostatic composite sponge of claim 1. ### Claim 17 (depends on 16) The method of claim 16, further comprising sterilizing the composite sponge. ### Claim 18 (depends on 1) The sponge according to claim 1, wherein the adherence-enhancing material forms a discontinuous layer on at least one surface of the porous sponge. ### Claim 19 (depends on 1) The sponge according to claim 1, wherein the adherence-enhancing material forms a continuous layer on at least one surface of the porous sponge. ### Claim 20 (depends on 1) The sponge according to claim 1, wherein the adherence-enhancing material is distributed throughout the porous sponge. ### Claim 21 A method of manufacturing a hemostatic composite sponge comprising providing a porous sponge of a matrix of a biomaterial; providing a material enhancing the adherence of said porous sponge to the applied tissue in the form of a suspension, a solution or powder, wherein said adherence-enhancing material is essentially free of a hydrogel forming component; and contacting the porous sponge and the adherence-enhancing material so that the adherence-enhancing material is stably associated with at least one surface of said porous sponge so that the hemostatic composite sponge is obtained, wherein the step of contacting the porous sponge and the adherence-enhancing material comprises first placing a grid onto the porous sponge and then distributing the adherence-enhancing material onto the porous sponge, such that the sponge is partially shielded from the adherence-enhancing material. ### Claim 22 (depends on 21) The method of claim 21, further comprising drying the composite sponge. ### Claim 23 (depends on 21) The method of claim 21, further comprising sterilizing the composite sponge. ### Claim 24 (depends on 21) The method according to claim 21, wherein the adherence-enhancing material is provided in the form of the suspension. ### Claim 25 (depends on 21) The method according to claim 21, wherein the adherence-enhancing material is provided in the form of the solution. ### Claim 26 (depends on 21) The method according to claim 21, wherein the adherence-enhancing material is provided in the form of the powder. ### Claim 27 (depends on 21) The method according to claim 21, wherein the adherence-enhancing material is present in an aqueous acidic solution, and the step of contacting the porous sponge and the adherence-enhancing material comprises allowing the porous sponge to absorb the aqueous acidic solution. ### Claim 28 (depends on 27) The method according to claim 27, wherein the adherence-enhancing material is present in the aqueous acidic solution at a concentration selected from the group consisting of 10 mg/cm3, 35 mg/cm3, 70 mg/cm3, and 100 mg/cm3. ### Claim 29 (depends on 21) The method according to claim 21, wherein the adherence-enhancing material is present in an ethanol solution, and the step of contacting the porous sponge and the adherence-enhancing material comprises allowing the porous sponge to absorb the ethanol solution. ### Claim 30 (depends on 29) The method according to claim 29, wherein the adherence-enhancing material is present in the ethanol solution at a concentration selected from the group consisting of 10 mg/cm3, 35 mg/cm3, 70 mg/cm3, and 100 mg/cm3.